Citations

Showing 10 of 107901 citations.

Outcome Analysis of Urethral Wall Stent Insertion With Artificial Urinary Sphincter Placement for Severe Recurrent Bladder Neck Contracture Following Radical Prostatectomy
Magera, James S., Inman, Brant A. , Elliott, Daniel S. , Inman, Brant A

Mayo Clinic

Journal of Urology | January 19, 2009 | Volume: 181 | Issue: 3 | Pages: 1236-1241

10.1016/j.juro.2008.11.011 | PMID 19152938 Get It

Health Care Reform: Why We Cannot Afford To Fail
Cortese, Denis A., Korsmo, Jeffrey O.

Mayo Clinic

Health Affairs | January 16, 2009 | Volume: 28 | Issue: Supplement 1 | Pages: w173-w176

10.1377/hlthaff.28.2.w173 | PMID 19151003 Get It

Long-Term Effects of Bilateral Oophorectomy on Brain Aging: Unanswered Questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging
Rocca, Walter A. , Shuster, Lynne T., Grossardt, Brandon R. , Maraganore, Demetrius M. , Gostout, Bobbie S., Geda, Yonas E. , Melton, L. Joseph, Geda, Yonas E , Grossardt, Brandon R

Mayo Clinic

Women's Health | January 16, 2009 | Volume: 5 | Issue: 1 | Pages: 39-48

10.2217/17455057.5.1.39 | PMID 19102639 Get It

In the Mayo Clinic Cohort Study of Oophorectomy and Aging, women who had both ovaries removed before reaching natural menopause experienced a long-term increased risk of parkinsonism, cognitive impairment or dementia, and depressive and anxiety symptoms. Here, we discuss five possible mechanistic interpretations of the observed associations; first, the associations may be non-causal because they result from the confounding effect of genetic variants or of other risk factors; second, the associations may be mediated by an abrupt reduction in levels of circulating estrogen; third, the associations may be mediated by an abrupt reduction in levels of circulating progesterone or testosterone; fourth, the associations may be mediated by an increased release of gonadotropins by the pituitary gland; and fifth, genetic variants may modify the hormonal effects of bilateral oophorectomy through simple or more complex interactions. Results from other studies are cited as evidence for or against each possible mechanism. These putative causal mechanisms are probably intertwined, and their clarification is a research priority.
Robotic Surgery for Cervical Cancer
Magrina, Javier F. , Zanagnolo, Vanna

Mayo Clinic

Yonsei Medical Journal | January 16, 2009 | Volume: 49 | Issue: 6 | Pages: 879

10.3349/ymj.2008.49.6.879 | PMID 19108008 Get It

Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
Martín, Miguel , Esteva, Francisco J. , Alba, Emilio , Khandheria, Bijoy K. , Pérez-Isla, Leopoldo, García-Sáenz, José Á. , Márquez, Antonia, Sengupta, Partho P. , Zamorano, José Luis , Isla, Leopoldo Pérez de , García-Sáenz, José A , Martin, Miguel , Alba, Emilio

Mayo Clinic

The Oncologist | January 16, 2009 | Volume: 14 | Issue: 1 | Pages: 1-11

10.1634/theoncologist.2008-0137 | PMID 19147689 Get It

Learning Objectives Analyze the clinical trial data for the treatment of breast cancer. Evaluate the risk of cardiotoxicity associated with the use of trastuzumab. Design and conduct a practical approach to managing patients with trastuzumab-associated cardiotoxicity. This article is available for continuing medical education credit at CME.TheOncologist.com.
FXR Promotes Endothelial Cell Motility Through Coordinated Regulation of FAK and MMP-9
Das, Amitava , Yaqoob, Usman , Mehta, Dolly , Shah, Vijay H. , Yaqoob, Usman

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | January 15, 2009 | Volume: 29 | Issue: 4 | Pages: 562-570

10.1161/atvbaha.108.182725 | PMID 19150878 Get It

Objective— Farnesoid X Receptor (FXR) mediates important signaling functions of bile acids in diverse cell types including those residing in the vascular wall. Indeed, recent work has identified FXR as a potential regulator of vascular structure and function in part through transcriptional activation of MMP-9. However, the signal transduction pathways linking bile acids to changes in actin cytoskeleton that are responsible for bile acid-induced vascular cell migration remain unexplored. Methods and Results— The FXR agonist and prototypical bile acid, chenodeoxycholic acid (CDCA), significantly increased endothelial cell (EC) motility, as analyzed by time lapse video microscopy, and tube formation, an in vitro correlate for angiogenesis. Increased cell motility was associated with prominent increases in focal adhesion (FA) plaques and was inhibited by FXR or MMP-9 siRNA, indicating a FXR-MMP-9-dependency of this signaling pathway. Mechanistically, incubation of cells with CDCA was associated with phosphorylation of a key FA protein, Focal Adhesion Kinase (FAK) at Y397 but not at Y576/577, or Y925. Studies using a site-specific phosphorylation mutant (phosphodeficient) of FAK revealed that FAK phosphorylation at tyrosine residue −397 was required for CDCA induced activation of the downstream FA assembly protein, paxillin. Lastly, siRNA-based silencing of FAK as well as phosphodeficient FAK mutant inhibited CDCA induced upregulation of MMP-9, cell motility, and vascular tube formation. Conclusion— Thus, this study demonstrates a pivotal role for FAK in the process of FXR-induced and MMP-9-dependent EC motility and vascular tube formation.
Capillary Hemangioma of the Testis
Talmon, Geoffrey A. , Stanley, Stephen M., Lager, Donna J.

Mayo Clinic

International Journal of Surgical Pathology | January 15, 2009 | Volume: 19 | Issue: 3 | Pages: 398-400

10.1177/1066896908323416 | PMID 19147509 Get It

Testicular hemangiomas are benign vascular neoplasms usually occurring in children. Pathologists must be aware of this entity when performing intraoperative frozen sections as, after diagnosis, testicle-sparing surgery is adequate. The authors present a typical case with immunohistochemical studies and a review of the literature.
Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2
Kottke, Timothy, Thompson, Jill , Díaz, Rosa María, Pulido, José S. , Willmon, Candice , Selby, Peter J. , Melcher, Alan , Harrington, Kevin J. , Vile, Richard G. , Coffey, Matt C. , Melcher, Alan A , Harrington, Kevin

Mayo Clinic

Clinical Cancer Research | January 15, 2009 | Volume: 15 | Issue: 2 | Pages: 561-569

10.1158/1078-0432.ccr-08-1688 | PMID 19147761 Get It

Abstract Purpose: The goals of this study were (a) to investigate whether preconditioning of immunocompetent mice with PC-61-mediated regulatory T-cell (Treg) depletion and interleukin-2 (IL-2) would enhance systemic delivery of reovirus into subcutaneous tumors and (b) to test whether cyclophosphamide (CPA), which is clinically approved, could mimic PC-61 for modification of Treg activity for translation into the next generation of clinical trials for intravenous delivery of reovirus. Experimental Design: C57Bl/6 mice bearing subcutaneous B16 tumors were treated with CPA or PC-61 followed by 10 injections of low-dose IL-2. Mice were then treated with intravenous reovirus. Virus localization to tumor and other organs was measured along with tumor growth and systemic toxicity. Results: Preconditioning with PC-61 and IL-2 enhanced localization of intravenous oncolytic reovirus to tumors with significantly increased antitumor therapy compared with controls (P < 0.01). However, with the maximal achievable dose of reovirus, Treg modification + IL-2 was also associated with systemic toxicity. CPA (100 mg/kg) did not deplete, but did functionally inhibit, Treg. CPA also mimicked PC-61, in combination with IL-2, by inducing “hyperactivated” NK cells. Consistent with this, preconditioning with CPA + IL-2 enhanced therapy of intravenously delivered, intermediate-dose reovirus to a level indistinguishable from that induced by PC-61 + IL-2, without any detectable toxicity. Conclusion: With careful reference to ongoing clinical trials with dose escalation of reovirus alone and in combination with CPA, we propose that future clinical trials of CPA + IL-2 + reovirus will allow for both improved levels of virus delivery and increased antitumor efficacy.
Protein Kinase C βII and PKCι/λ: Collaborating Partners in Colon Cancer Promotion and Progression
Murray, Nicole R. , Weems, Justin, Braun, Ursula, Leitges, Michael , Fields, Alan P. , Leitges, Michael

Mayo Clinic

Cancer Research | January 15, 2009 | Volume: 69 | Issue: 2 | Pages: 656-662

10.1158/0008-5472.can-08-3001 | PMID 19147581 Get It

Abstract We previously showed that elevated expression of either protein kinase CβII (PKCβII) or PKCι/λ enhances colon carcinogenesis in mice. Here, we use novel bitransgenic mice to determine the relative importance of PKCβII and PKCι/λ in colon carcinogenesis in two complimentary models of colon cancer in vivo. Bitransgenic mice overexpressing PKCβII and constitutively active PKCι (PKCβII/caPKCι) or kinase-deficient, dominant-negative PKCι (PKCβII/kdPKCι) in the colon exhibit a similar increase in colon tumor incidence, tumor size, and tumor burden in response to azoxymethane (AOM) when compared with nontransgenic littermates. However, PKCβII/kdPKCι mice develop predominantly benign colonic adenomas, whereas PKCβII/caPKCι mice develop malignant carcinomas. In contrast, PKCβ-deficient (PKCβ−/−) mice fail to develop tumors even in the presence of caPKCι. Our previous data indicated that PKCβII drives tumorigenesis and proliferation by activating β-catenin/Apc signaling. Consistent with this conclusion, genetic deletion of PKCβ has no effect on spontaneous tumorigenesis in Apcmin/+ mice. In contrast, tissue-specific knockout of PKCλ significantly suppresses intestinal tumor formation in Apcmin/+ mice. Our data show that PKCβII and PKCι/λ serve distinct, nonoverlapping functions in colon carcinogenesis. PKCβII is required for AOM-induced tumorigenesis but is dispensable for tumor formation in ApcMin/+ mice. PKCι/λ promotes tumor progression in both AOM- and Apcmin/+-induced tumorigenesis. Thus, PKCβII and PKCι, whose expression is elevated in both rodent and human colon tumors, collaborate to drive colon tumor formation and progression, respectively. [Cancer Res 2009;69(2):656–62]
Management of the Athlete With Acute Anterior Cruciate Ligament Deficiency
Hurd, Wendy J., Axe, Michael J. , Snyder‐Mackler, Lynn

Mayo Clinic

Sports Health: A Multidisciplinary Approach | January 14, 2009 | Volume: 1 | Issue: 1 | Pages: 39-46

10.1177/1941738108326977 | PMID 23015853 Get It

Background: Identification of highly active individuals early after acute anterior cruciate ligament deficiency who are good candidates for nonoperative management is a clinical challenge. The University of Delaware has developed and validated a treatment algorithm and screening examination to distinguish between nonoperative and surgical candidates. Study Design: Review. Evidence Acquisition: A description of the decision-making rules and rehabilitation protocol for highly active individuals with anterior cruciate ligament deficiency is provided. Results from clinical trials, outcome studies, and biomechanical investigations conducted using the treatment algorithm and screening examination are also reviewed. Results: Patients identified as nonoperative rehabilitation candidates using these clinical guidelines have a far greater success rate than what has been reported when patients self-select nonoperative management. Furthermore, nonoperative outcomes are improved when patients participate in a perturbation-enhanced rehabilitation protocol. Divergent lower extremity movement patterns are consistent with the different functional abilities of the dichotomous patient groups identified with the screening examination. Conclusion: Given the differential patient response to anterior cruciate ligament injury, implementation of the decision-making guidelines discussed in this review offers clinicians the opportunity to provide individualized patient care rather than continuing with a blanket surgical treatment strategy.